News Briefs

October 2019 News Briefs

AMA Grants CPT-PLA Code for KidneyIntelX™ The American Medical Association (AMA) has granted a CPT® (Current Procedural Terminology) Proprietary Laboratory Analyses (PLA) Code for KidneyIntelX™, the lead product from RenalytixAI. The new code, 0105U, has been approved and published by the AMA CPT Editorial Panel, effective October 1, 2019. According to a press release from RenalytixAI, a payment rate for ... Read More »

September 2019 News Briefs

Tamara Kear Named ANNA Executive Director Tamara Kear, PhD, RN, CNS, CNN, has been named executive director of the American Nephrology Nurses Association (ANNA). Currently ANNA’s president, Dr. Kear will assume her new position at Anthony J. Jannetti, Inc. (AJJ, Inc.), on January 1, 2020. AJJ, Inc. provides full-service management services to ANNA. As executive director, Dr. Kear will oversee ... Read More »

July / August 2019 News Briefs

FDA Grants Breakthrough Designation for KidneyIntelX™ The US FDA has granted the designation Breakthrough Device to RenalytixAI for its lead diagnostic KidneyIntelX™. According to a press release from RenalytixAI, this is the first such designation for an AI-enabled diagnostic tool for kidney disease announced by any company. In an effort to curtail the estimated $114 billion annual cost of chronic ... Read More »

May / June 2019: News Briefs

Supplemental New Drug Application for INVOKANA® Submitted Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration seeking a new indication for INVOKANA® to reduce the risk of end-stage renal disease, the doubling of serum creatinine, and renal or cardiovascular death in adults with type 2 diabetes and ... Read More »

April 2019 News Briefs

WavelinQ™ 4F EndoAVF System Receives 510(k) Clearance from FDA In February, BD (Becton, Dickinson and Company), a global medical technology company, received 510(k) clearance from the US Food and Drug Administration for the BD WavelinQ™ 4 French (4F) endoAVF system. The system is a recent innovation in endovascular arteriovenous fistula (endoAVF) creation technology; it allows for the creation of an ... Read More »

Clinical Validation Study for KidneyIntelX™ Announced

In a recent press release, RenalytixAI announced the initiation of its clinical validation study for KidneyIntelX™. RenalytixAI develops artificial intelligence-enabled diagnostics for kidney disease. KidneyIntelX is designed to diagnose and improve clinical management of patients with type 2 diabetes and those of African ancestry with fast-progressing kidney disease. The expanded validation study program includes investigators from Johns Hopkins Medicine, Emory ... Read More »

RenalytixAI Developing AI-Enabled Clinical Diagnostic Products for Kidney Disease

RenalytixAI, a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, has raised $29 million to support the development and commercialization of two product categories for the early detection of kidney disease and accurate management of kidney transplant rejection. The launch of the first product, KidneyIntelX™, is planned for 2019; the launch will be conducted in collaboration with the Icahn ... Read More »

Specialist Nephrology Care Would Decrease US Health Care Costs

The RAND Corporation has released results from a recent analysis demonstrating that providing specialized medical care and coordination in patients with reduced kidney function prior to the need for dialysis treatment could save the US health care system more than $1 billion each year. According to a press release from the RAND corporation, approximately 60% of the savings would be ... Read More »

October 2018 News Briefs

Fresenius Awards $100,000 Grant to ANNA in Celebration of Nephrology Nurses Week   In recognition of the 50th anniversary year of the American Nephrology Nurses Association (ANNA) and in honor of Nephrology Nurses Week, September 9-15, Fresenius Medical Care North America has awarded ANNA a $100,000 grant. According to a press release from Fresenius Medical Care North America, the award ... Read More »

September 2018: News Briefs

Study 206 Begins Treatment of Patients with ALLN-177 for Hyperoxaluria Allena Pharmaceuticals, Inc., a late-stage biopharmaceutical company specializing in oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, has announced that the first patients have been enrolled and are being treated in a phase 2 basket study of ALLN-177. According to a press release, Study ... Read More »